|Day Low/High||43.10 / 43.87|
|52 Wk Low/High||36.76 / 45.84|
While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
New Cardiac Ablation Catheter Integrates with 3D Mapping System to Advance the Treatment of Atrial Fibrillation
From Abbott Labs to Wynn, these names rate checking out.
THE NEW CONFIRM RX™ ICM AUTOMATICALLY CAPTURES VITAL CARDIAC INFORMATION AND RELAYS DATA TO PHYSICIANS VIA THE MYMERLIN™ MOBILE APP ENABLING REMOTE MONITORING OF IRREGULAR HEART RHYTHMS
It's a wonder to me how split this market really is.
- FREESTYLE® LIBRE SYSTEM ELIMINATES ROUTINE FINGER STICKS(1) FOR GLUCOSE MEASUREMENTS AND REQUIRES NO FINGER STICKS FOR CALIBRATION
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.
- RESEARCH SHOWS THAT STAYING NOURISHED IN THE DAYS AND HOURS PRIOR TO A PROCEDURE CAN HELP PATIENTS PREPARE FOR AND RECOVER FROM SURGERY
Jim Cramer says he respects Buffett's judgment. Cramer's also bullish on some airline stocks.
Jim Cramer says a rally on French election results is fine, but don't forget great U.S. corporate earnings and merger activity.
Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.
Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.
Earlier market optimism faded as Wednesday wore on and a financials rally gave way to a selloff in Dow Jones Industrial Average component IBM and energy shares.
The S&P 500 hugs the flatline on Wednesday afternoon as a selloff in crude oil prices and energy shares counters better-than-expected earnings from Morgan Stanley.
Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.
Earnings drive markets again on Wednesday with IBM dragging on the Dow Jones Industrial Average and Morgan Stanley driving financials, and broader markets, higher.
It really is that simple. Mr. and Ms. Market no longer trust the outlook for domestic economic growth.
Pfizer launched a Remicade biosimilar in November.
JNJ has been busy integrating newly acquired businesses.
JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.
From Aetna to United Technologies, these names are hot.
Their overseas business has been carrying them.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.